Expandable stent

Abstract
An expandable stent comprising a tubular body made up of a plurality of separated tubular elements (1) arranged along a common longitudinal axis. Each tubular element (1) comprises a plurality of rhombic-shaped closed cell elements (2) joined by circumferentially extending linking members (3). The closed cell elements (2) are expandable to allow the tubular elements, and hence the stent itself, to expand. In the direction of the longitudinal axis of the stent, the extremities of each of the closed cell elements has an enlarged loop (30) with waisted portions (33) which allow the tubular elements to interlock to create a stable structure, at least when in the unexpanded condition.
Description

This invention relates to an expandable tubular stent for implantation in the lumen of a body duct in order to ensure a passage therein.


Such stents are used mainly in the treatment of blood vessels exhibiting stenoses, and more generally in the treatment of diseases of various anatomical ducts of the human or animal body, such as, for example, the urinary ducts, especially the urethra, or the digestive ducts, especially the esophagus.


The percutaneous implantation of an expandable tubular stent in a stenotic blood vessel is generally recommended, for example after a conventional angioplasty procedure, for preventing the dilated vessel from closing up again spontaneously or for preventing its occlusion by the formation of a new atheromatous plaque and the possible recurrence of stenosis.


A known type of expandable tubular stent consists of an assembly of radially expandable, tubular elements aligned along a common longitudinal axis and successively joined together in pairs by respective sets of linking members. Such a stent is disclosed, for example, in international patent application WO 98/58600 in which each of the tubular elements consists of a strip forming a zigzag corrugation defining bent extreme portions which are successively connected together in pairs in opposite directions by rectilinear intermediate portions. By virtue of this zigzag corrugation, the stent is expandable between a first, unexpanded state, enabling it to be implanted percutaneously by means of an insertion device of reduced diameter, and a second, expanded state, in which the stent makes it possible to ensure a passage in the lumen of the body duct. Stents of this type are also disclosed in international patent applications WO 96/26689 and WO 98/20810.


To install the stent, it is placed in the unexpanded state on an angioplasty balloon catheter. Once in place, the balloon is inflated in order to cause the stent to expand. Alternatively, the stent may be made from a material which has a recovery capacity, so that the stent may automatically expand, once in place.


According to the invention there is provided a stent comprising a tubular body made up of a plurality of separate, radially expandable, tubular elements aligned along a common longitudinal axis, wherein at least some of the tubular elements each comprise a plurality of closed cell elements, each joined to the next by a circumferentially-extending linking member.


It will thus be seen that each tubular element comprises a closed loop consisting of a series of alternating closed cell elements and circumferential linking members.


In most known stents, the tubular elements are physically linked to one another by longitudinally extending linking members. One or more of such longitudinally extending linking members may link each pair of adjacent tubular elements. However, there are a number of advantages to be obtained by not using longitudinally-extending linking members, so that the stent consists simply of a collection of separate tubular members whose alignment along a common axis to form the stent is achieved by other means. Preferably the tubular elements, as well as being expandable, are also compressible.


By “separate” is meant that the tubular elements are not directly connected together by longitudinally-extending linking members. The word “separate” does not imply that the elements may not touch and, as will be explained below, in certain conditions of the stent, the linking members will touch and will indeed link together. In the absence of longitudinally-extending linking members, the structural integrity of the stent is realised by alternative means, such as:


1) A tubular member or framework which is not directly joined to the adjacent tubular elements but over which or within which the tubular elements are positioned in the desired alignment. For example, the balloon which is used to expand the stent can be used to maintain the position of the tubular members with respect to one another.


2) Interlock means which mechanically holds the tubular members together even though they are not directly joined. An example of this would be to provide co-operating interlock means on the tubular elements themselves.


In an embodiment of the invention, both these techniques are employed: the tubular elements are placed over the balloon and interlocked together so that the stent remains structurally stable during its often tortuous passage to the treatment site. Upon expansion, the interlocking is released, and the balloon alone then maintains the positional stability of the stent components. After the balloon has been deflated, the expanded stent, which has undergone plastic deformation, maintains its expanded shape and thus keeps the vessel being treated at its desired diameter. The expanded vessel applies a reaction force, due to its elastic nature, against the stent and thus maintains the position of the individual tubular elements making up the stent with respect to one another.


In order to allow the stent to expand it is necessary that the tubular elements be radially expandable. For this purpose, each tubular element is constructed in such a way that it is expandable in the circumferential direction. This may be achieved by the closed cell construction of the invention in which the expansion capabilities of the tubular elements are contained wholly or primarily in the closed cell elements. To avoid out of balance forces during expansion, it is preferred that the closed cell elements be positioned symmetrically with respect to the circumferential linking members, but asymmetric arrangements are also possible.


The tubular elements making up the stent may be all identical, or they may be different—for example, a stent could be made up of a combination of tubular elements comprising closed cell elements, and tubular elements constructed in some other way, arranged to create particular desired properties of the stent as a whole.


The circumferential linking members may simply consist of rectilinear members extending in the circumferential direction. Alternatively the circumferential linking members may be angled to the circumferential direction, so long as they have a component in the circumferential direction so that the adjacent closed cell elements are spaced apart in the circumferential direction. In a further alternative, the circumferential linking members are not rectilinear, but are some other shape to create particular desired characteristics—for example, the circumferential linking members could be such as to provide a degree of flexibility in the circumferential direction, although the expansion capabilities of the tubular element will still be primarily due to the closed cell elements. Preferably, all of the circumferential linking members are the same length in the circumferential direction so that the closed cell elements are evenly distributed about the circumference of the tubular element.


The circumferential linking members attach to the closed cell elements at respective spaced attachment points, and each closed cell element is constructed in such a way that it is capable of expanding from a first position in which the attachment points are relatively close together to a second position in which the attachment points are relatively further apart. In this way, the circumferential length of the tubular element can be increased from a relatively low value, corresponding to the unexpanded condition of the stent, to a relatively higher value, corresponding to the expanded condition of the stent. In one possible construction, each closed cell element comprises two individual members extending between said attachment points, said members being spaced apart in the direction of the longitudinal axis of the stent. Thus, one of said members may be said to be the proximal member, the other the distal member. The proximal and distal members are preferably symmetrically arranged about a straight line joining the two attachment points, this line being coaxial around the circumference with the general direction of the circumferential linking members.


The proximal and distal members are capable of bending in order to enable the expansion of the closed cell element from the first position to the second position. This may be achieved in various ways. For example, each of the proximal and distal members may be fabricated from a flexible member which is thus able to bend to accommodate the required movement. Alternatively, each of the proximal and distal members is fabricated by a plurality of relatively rigid side members joined by hinge members. In the preferred embodiment, each of the proximal and distal members comprises two such side members joined together by a hinge. Preferably the two side members are of equal length, but they do not need to be; however, for a symmetric construction the corresponding side members in each of the proximal and distal members should be of equal length.


In an embodiment, each closed cell element has a generally rhombic or diamond shape, comprising four side members of relatively stiff construction, joined by four hinge members corresponding to the corners of the rhombus. The circumferential linking members attach to the closed cell element at the location of opposite hinge members. Thus, each circumferential linking member has, at one end, one of the hinge members of one closed cell element and, at the opposite end, the opposite hinge member of the adjacent closed cell element.


It is not essential that all the closed cell elements in each tubular element are the same shape. In an alternative embodiment every other closed cell element is of rhombic shape, as described above, whilst the closed cell elements in between comprise “double rhombic” elements, each comprising two rhombic shapes, as described above, aligned in the circumferential direction, but joined by a narrow, but not closed, neck portion.


Other arrangements of closed cell elements are possible, according to the circumstances.


The aforesaid interlock means can conveniently be provided by providing an enlarged portion at each of the hinge members to which the link members are not attached. The narrowing side members as they approach each hinge member, together with the respective enlarged portion, form a narrow or waist portion which can overlap with an enlarged portion from the next adjacent tubular element. Two such waist portions acting together can thus retain an enlarged portion from the next adjacent tubular element.


The interlock means do not have to be provided on every closed cell element. It may be adequate to provide them on just a few closed cell elements, but evenly spaced about the circumference, so as to give a balanced attachment between adjacent tubular elements. For this purpose some of the closed cell elements may extend further in the axial direction of the stent than the remaining closed cell elements, so that these extended portions may interlink with the adjacent tubular element.


This enlarged portion can be formed as a flexible open cell with a narrowed neck, or can be formed as a relatively rigid block, from which, for example, the two side members may emerge via a respective narrowed portion to act as a hinge—in this latter case, the hinge member actually consists of two separate hinges.


In current medical practice, it is often the case that, in addition to its role in providing ongoing support for the vessel wall, the stent is required to act as a means whereby therapeutic agents may conveniently be applied. Indeed the trauma caused during the angioplasty procedure may call for localised drug treatment. In addition, drugs may be used to counteract restenosis, and for other purposes. Conventionally, such therapeutic agents are contained within some form of coating which is applied to the stent so that the drug will be released over a period of time. One problem with such an arrangement, however, is that, whereas the drug needs primarily to be applied through the wall of the vessel being treated, in practice as much of the drug is released into the fluid, e.g. blood, flowing within the vessel as passes through the vessel wall. Not only is the drug which is washed away effectively wasted, it can also do positive harm elsewhere if, for example, it enters a sensitive organ such as the heart.


Thus, in an embodiment of the invention the stent is equipped with wells opening into its exterior surface—that surface which, when the stent is in place, will face the wall of the vessel being treated—said wells being suitable to contain therapeutic agent.


The wells may comprise holes or grooves opening into the exterior surface of the stent, and may or may not pass right through the material of the stent to the interior of the stent. However, if the wells pass through to the interior of the stent there is clearly a danger of at least some of the drug being released into the fluid flowing within the vessel. Therefore it is preferred that, in such a case, that end of the well which opens into the interior of the stent is constructed, for example by being made narrower, and/or being plugged by a material which prevents or considerably reduces the tendency of the therapeutic agent to flow therethrough.


Thus it is preferred that the well is wholly or primarily open to the exterior surface of the stent so that the therapeutic agent may act directly on the wall of the vessel and does not get washed away by the fluid flowing along the vessel being treated.


The wells may open onto any suitable exterior surface of the stent. For example, the wells may conveniently be formed in the blocks which form the enlarged portions of the closed cell elements. For example, each block could be formed with a well in the form of a hole, which may or may not be a through hole and which opens into that surface of the block which forms part of the exterior surface of the stent. Alternatively the wells may be formed as grooves in the side members of the closed cell elements, the grooves opening into that surface of the side members which forms part of the exterior surface of the stent. It will be understood, however, that the above positions are given just as examples.


As mentioned above, the wells contain therapeutic agents which are intended to be released at a controlled rate against the wall of the vessel being treated. Not all of the wells necessarily will contain the therapeutic agent, and not all wells need to contain the same therapeutic agent. It is possible, for example, that the wells of different tubular elements contain different therapeutic agent, opening up the possibility of providing mixtures of drugs by choosing particular tubular elements carrying particular drugs to make up the stent. Clearly this is particularly easy with a stent in which the tubular elements are separate from one another. The therapeutic agents may also be provided in separate layers within the well, with the drug needed first being in the top layer, and the drugs needed later in lower layers, in correct sequence.


In addition, it is possible to provide that some of the wells contain therapeutic agents which have different rates of release. For example the drug contained in the wells of those tubular elements at or near the ends of the stent could be arranged to have a more rapid or a slower release rate than the remainder.


The therapeutic agents may be provided in any suitable form for retention in the wells, and for sustained release, once installed within the vessel. Examples are liquid, gel or powder form.





In order that the invention may be better understood, several embodiments thereof will now be described by way of example only and with reference to the accompanying drawings in which:



FIG. 1 is a two-dimensional view of the evolute of the surface of a stent according to a first aspect of the present invention, in its “as cut” condition;



FIG. 2 is a view corresponding to FIG. 1, but showing just a single tubular element;



FIG. 3 is an enlarged view of one of the closed cell elements in the embodiment of FIG. 1;



FIGS. 4A and B are side and perspective views of the stent of FIG. 1, but in which the number of elements is just three, in its “as cut” condition;



FIG. 5 is a perspective view of a single tubular element from the stent of FIG. 1;



FIGS. 6 and 7 are views similar to FIGS. 4A and 48 respectively, but showing the stent in the crimped condition;



FIGS. 8 and 9 are views similar to FIGS. 4A and 48 respectively, but showing the stent in the expanded condition;



FIGS. 10 and 11 are views similar to FIG. 4B, but showing two further embodiments showing both the first and second aspect of the invention;



FIG. 12 is a view similar to FIG. 2 showing a still further embodiment of the invention;



FIGS. 12A, B and C are views on the lines A-A, B-B and C-C respectively of FIG. 12;



FIG. 13 is a view similar to that of FIG. 5, but showing the embodiment of FIG. 12;



FIG. 14 is an enlarged view of part of FIG. 13;



FIG. 15 is a view similar to FIG. 2 showing a still further embodiment of the invention;



FIGS. 15A and B are views on the lines A-A and B-B respectively of FIG. 15;



FIG. 16 is a view similar to that of FIG. 5, but showing the embodiment of FIG. 15;



FIG. 17 is an enlarged view of part of FIG. 16;



FIG. 18 is a view similar to FIG. 2 showing a still further embodiment of the invention;



FIG. 18A is a view on the line A-A of FIG. 18;



FIG. 19 is a view similar to that of FIG. 5, but showing the embodiment of FIG. 18;



FIG. 20 is a view similar to FIG. 2 showing a still further embodiment of the invention;



FIG. 21 is a view similar to FIG. 5, but showing the embodiment of FIG. 20;



FIG. 22 is a view similar to FIG. 2 showing a still further embodiment of the invention;



FIG. 23 is a view similar to FIG. 5, but showing the embodiment of FIG. 22; and



FIG. 24 is a view similar to FIG. 4b, but showing the embodiment of FIG. 22.





Referring firstly to FIGS. 1 and 4, the stent comprises a series of radially expandable tubular elements 1 aligned along a common longitudinal axis. Both of these Figures show the stent in its “as cut” condition by which is meant the condition in which it comes out of the manufacturing process. FIG. 1 illustrates the stent folded out in two dimensions, illustrated by the X-Y coordinates printed to the side of the drawing. In practice the stent is, of course, a three dimensional object, as illustrated in elevation and in perspective in FIGS. 4A and 4B respectively; thus it is assumed that the ends 12, 13 of each tubular element in FIG. 1 are in fact joined so that each element forms a closed loop of generally tubular configuration. In this description the longitudinal direction of the stent is parallel to the X-axis illustrated in FIG. 1, while the circumferential direction of the stent is parallel to the Y-axis in FIG. 1.


It will be noted that the tubular elements 1 are separate from one another in the sense that there is no direct physical link between them, keeping the tubular elements 1 in position. Instead alternative means are used to maintain the structural integrity of the stent. This will be explained in more detail below.


In the stent illustrated, all of the tubular elements are identical in structure and size although, as mentioned above, this need not necessarily be the case. A single tubular element 1 is shown, in two dimensional form in FIG. 2, and in three dimensional form in FIG. 5. Each tubular element comprises a plurality of closed cell elements 2 equally spaced apart by circumferentially extending linking members 3. In the embodiment illustrated each tubular element 1 comprises six closed cell elements 2, spaced apart circumferentially by 60°, but other numbers of closed cell elements are possible, according to the circumstances.


A single closed cell element 2 is shown in enlarged detail in FIG. 3. The closed cell element has a generally rhombic or diamond shape defined by four side members 24 to 27 joined together by respective hinge members 20 to 23. The circumferential linking members 3 attached to respective opposite hinge members 21, 23.


The hinge members 21, 23 are formed by narrowed sections 28, 29 where the respective side members 24/27, 25/26 join the respective linking member 3. The hinge members 20, 22 are formed as a loop 30 having a narrowed opening 31 into the interior 32 of the cell element. This narrowed opening 31 corresponds to a waisted portion 33 which cooperates in the interlocking of individual tubular elements 1, as will be explained below.


Before the stent is used, it will generally be crimped to the balloon which will carry it to the treatment site and subsequently expand it. The crimping process involves compressing the “as cut” stent onto the balloon so that it is securely gripped. During compression the diameter of the tubular elements, decreases and this is achieved by a deformation of the closed cell elements 2 in such a way as to tend to close the elements up—i.e. so that the hinge members 21 and 23 move towards one another, thus reducing the circumferential length of the tubular element 1. During this process the closed cell elements bend at the hinge members 20 to 23. The crimped condition of the stent is illustrated in FIGS. 6 and 7 and since, in effect, the stent is expanded from this condition, the crimped condition can also be regarded as the unexpanded condition of the stent.


It will be noted in FIGS. 6 and 7 that, in the crimped condition of the stent, the hinge members 20, 22 belonging to adjacent tubular elements are interlocked, thus maintaining the structural integrity of the stent as a whole. This interlocking is achieved by the cooperating interlocking shapes of the hinge members 20, 22 in which each of the enlarged loops 30 lie between a pair of waisted portions 33 belonging to circumferentially adjacent closed cell elements 2 belonging to the same tubular element 1. By careful design, the closed cell elements can be configured to grip one another to maintain the shape of the stent so that it is not dislodged or deformed during its often long and tortuous passage to the treatment site. The longitudinal flexibility of the stent is ensured in the crimped condition by the fact that each loop 30 is allowed to move longitudinally a short but controlled distance towards the adjacent linking member 3. Thus, as the stent is bent longitudinally the loops 30 on one side move slightly, as described, whilst those on the other side move in the opposite direction. In an alternative embodiment (not shown) still greater longitudinal flexibility can be achieved by arranging that the elements are interlocked in such a way as to allow the loops to move, in a controlled manner, in either longitudinal direction.


When the stent reaches the treatment site, and the physician is satisfied as to its correct position, the balloon carrying the stent is expanded, in the known manner, to expand the stent from its condition shown in FIGS. 6 and 7 to its dilated condition shown in FIGS. 8 and 9. During this expansion process, the closed cell element 2 deform to a final shape clearly illustrated in FIG. 8. It will be seen that the hinge members 21, 23 have moved apart in the circumferential direction, thus increasing the circumferential length of each tubular element 1. At the same time, the hinge members 20, 22 of adjacent closed cell elements 2 move apart in the circumferential direction thus releasing the grip which they had previously exerted on the corresponding members of adjacent tubular elements. The stent however by now is supported both from within and without and so maintains its structural shape, even though the interlocking is released. The support from within comes from the balloon which is being internally pressurised to expand the stent; the support from without comes from the wall of the vessel being treated.


It will also be noted that, during expansion, the length, in the longitudinal direction of the stent, of each of the closed cell elements 2 reduces and this effect, in a stent with linking members between adjacent tubular elements, causes the overall length of the stent to reduce. This reduction in length is undesirable for various reasons, and it will be seen that the use of independent tubular elements 1 substantially eliminates this problem.



FIGS. 10 and 11 show modified versions of the stent of FIG. 1 in which the hinge members 20, 23 are modified from the open loop form described previously.


The stents of FIGS. 10 and 11 differ from that of FIG. 1 in that the hinge members 20, 22 comprise a block 34 of material from which the side members 24/27 and 25/26 emerge, via a respective narrowed portion to act as a hinge. Thus, in this case the hinge members 20, 22 each comprise a pair of hinges by which the respective side members 24/27 and 25/26 are attached to the blocks 34. Preferably these blocks 34 are formed integrally with the remainder of the tubular element, and are of the same material.


The difference between the embodiments of FIGS. 10 and 11 is in the shape of the blocks 34 which in the case of FIG. 10 is substantially rectangular and in the case of FIG. 11 is substantially circular. In both cases, each block 34 acts as an enlarged end in a similar manner to loop 30 of the FIG. 1 embodiment, and defines a narrowed waist portion where it joins the adjacent side members. The arrangement is thus able to interlock the individual tubular elements 1 in the same way as described above.


The advantages of a stent with independent tubular elements over one in which the tubular elements are linked by linking members can be summarised as follows:


1) Manufacture is made easier because only a basic tubular element has to be cut. Any stent length can readily be created by adding the appropriate number of tubular elements at the commencement of the assembly or crimping process.


2) The crimped stent has a high degree of longitudinal flexibility since it is not restrained by the inter-element linking members of known stents.


3) The crimped stent has a high degree of longitudinal conformability due to its tubular elements being interlocked at multiple cell locations.


4) There is substantially no shortening of the stent during expansion because the shortening of each tubular element does not affect the stent as a whole.


5) Once deployed, the stent has a high degree of longitudinal flexibility and of longitudinal and radial conformability due to the absence of the restraint imposed by inter-element linking members.


6) Once deployed the stent has a good vessel repartition and vessel scaffolding, with homogeneous support for the vessel wall—see particularly FIG. 8.



FIGS. 10 and 11 also illustrate the use of wells for containing therapeutic agent. It will be seen that, in each of FIGS. 10 and 11 the blocks 34 have formed on their exterior surface a well 35 which is intended to act as a reservoir for a therapeutic agent. Each well 35 takes the form of a shallow blind hole which opens into the exterior surface which, when the stent is deployed faces the wall of the vessel being treated.


Thus, any therapeutic agent contained within the wells 35 acts directly on the wall of the vessel, and is not substantially affected by the flow of fluid within the vessel.


Although only a single well 35 is formed in each block 34, it is possible for multiple smaller wells to be formed, perhaps each containing different drugs. Different drugs can be supplied on different tubular elements, making it easy to create a stent, as needed, containing an appropriate recipe of drugs.


The holes making up the wells 35 can be formed as through-holes, and plugged from the interior side to create a blind hole. Alternatively, the through hole can be left, and a suitable substance which will resist the washing away of the drug contained within the well can be deposited at the inner end of the through hole.


Although the wells 35 are shown as circular holes, it will be understood that other shapes are possible, including multi-sided, square or rectangular. Alternatively, the wells can be formed as grooves or slots opening into the exterior surface of the block 34.


The wells may additionally or instead of be provided at other locations, such as on the side members 24 to 27 of the closed cell elements 2. However, for this purpose, the side members would have to be made less deformable than they might otherwise be since any deformation of the reservoir during stent crimping or deployment might result in delamination of the reservoir contents, which would be undesirable. The blocks 34 are seen as attractive since they suffer substantially less deformation than other parts of the stent because their bulk, relative to the remaining components of the stent, is such that they are relatively stiff.



FIGS. 12 to 19 illustrate further embodiments similar to that of FIGS. 10 and 11, showing alternative arrangements of wells.


In the embodiment shown in FIGS. 12 to 14, two shapes of wells are shown. Half of the wells 35 have the shape of a short slot 36 which opens only into the exterior surface of the tubular element; the other half of the wells 35 have the shape of a slot 37 which opens both into the exterior surface of the tubular element 1, but also into the edge of the tubular element 1. Various combinations of these shaped wells can be used.


The enlarged view of FIG. 14 is of interest in that it clearly shows the structure of the left-hand hinge member 20. This can be seen to comprise two narrowed (i.e. less wide) portions 50, 51 where the respective side members 24 and 27 join the block 34.


In the embodiment of FIGS. 15 to 17, there is again a combination of different well shapes: a first type of well 35 formed of a short slot 38 extending in the circumferential direction of the stent; a second type of well 35 formed of a slot 39 which extends right across the block 34 in the circumferential direction of the stent, and is open at both ends.



FIGS. 18 and 19 show an embodiment in which again two different styles of well 35 are shown. On the left hand side: a block 40 is formed within the loop 30 of a hinge member of the type described above in relation to the embodiment of FIG. 1. The block 40 is formed with a well 35 formed as a blind hole, in a similar manner to the wells 35 of the embodiment of FIG. 11.


On the right hand side a block 41 is formed outside of the loop 30 and, once again, is equipped with a well 35 in the form of a blind hole. Since there is room beyond the hinge members 20, 22, the block 41 does not interfere with the interlocking of the tubular element 1 together during crimping, as described above.


The advantages of stents incorporating wells, as described above, can be summarised as follows:


1) The well can hold drugs without the need for a polymer matrix coating. The use of wells can eliminate coating delamination during stent deployment, thus reducing the risk of thrombosis.


2) The absence of a polymer matrix coating eliminates any potential biocompatibility problems arising from their use.


3) Once the stent is fully deployed, the outside surface of the stent is pushed against the wall of the vessel being treated; this means that the well is open only towards the vessel wall, to enable diffusion of the drugs into the vessel wall. In addition, the drug cannot be washed out by the flow of fluid in the vessel and so cannot have undesired effects elsewhere.


4) Compared to a thin (0.1-5 micron) drug layer coated on the stent, the reservoir can be loaded with a high dose and long life time.


5) The reservoir dimensions (diameter, length, width, depth) can be readily varied to the particular circumstances such as blood flow direction and drug release kinetics.


6) Each well can contain a single drug and therefore different drugs can be individually held in different wells without the danger of their reacting with each other.



FIGS. 20 to 24 show two further embodiments in which the closed cell elements in each tubular element 1 are not all identical, and in which the locating means are not provided on every closed cell element.


Referring to FIGS. 20 and 21, there is shown an embodiment in which each tubular element 1 is made up of two different shapes of closed cell element which alternate around the tubular element. The first shape of closed cell element, illustrated under reference 50 is similar to that of the closed cell elements described above with reference to FIG. 3, except that the loops 30 on one side of the rhombic shaped structure are positioned at the end of a pair of extended arms 51, 52. As a result these “extended” loops 30 protrude, in the axial direction of the stent, with respect to the remaining parts of the tubular element 1, and are thus able to interlock with the next adjacent tubular element.



FIGS. 22 to 24 illustrate an embodiment similar to that of FIGS. 20 and 21 but in which the extended loops 30 are open at their neck, as distinct from the arrangement in FIGS. 20 and 21, where each extended loop 30 takes the form of a closed ring which is attached at the ends of the arms 51, 52.


In both embodiments, the closed cell elements between the elements 50 are of different shape to the elements 50. These elements, given the reference 53, each comprise two rhombic-shaped sections 54, 55 which are joined by a narrow open neck portion 57.


The joining of adjacent tubular elements is shown in FIG. 24. FIG. 24 actually shows the embodiment of FIGS. 22 and 23, but it will be understood that the same interlocking technique can be used for the embodiment of FIGS. 20 and 21. In relation to FIG. 24, it should also be noted that the drawing shows the tubular elements in their expanded state—i.e. in a state in which they would not ordinarily be interlocked—see above.


The aperture 56 formed within the loop 30 in the embodiment of FIGS. 20 and 21 could be used as a well for containing a therapeutic, agent, in the manner described above. For this purpose, the aperture 56 may be a through aperture, plugged at its inner end, or may be a blind bore, opening into the outer surface only.


The stent which has been described is expandable between an unexpanded state (in practice, probably the crimped condition mentioned 10 above), in which it is able to be guided inside the lumen through a body duct, such as a blood vessel, for example, and an expanded state, in which the stent, after a uniform expansion, comes into contact with the inner wall of the body duct, defining a passage of approximately constant diameter inside said duct.


The stent will generally be forcibly expanded mechanically under the action of a force exerted radially outwards, for example under the effect of the inflation of a balloon. However, the stent may be of the “auto-expandable” type, i.e. capable of changing by itself from a first, unexpanded condition under stress, enabling it to be guided through the body duct, to a second, expanded, working condition.


The stent may be made of any material compatible with the body duct and the body fluids with which it may come into contact.


In the case of an auto-expandable stent, it will be preferable to use a material with a recovery capacity, for example, stainless steel, Phynox® or nitinol.


In the case of a stent utilising a forced expansion, a material with a low elastic recovery capacity may be used to advantage. Examples are metallic materials such as tungsten, platinum, tantalum, gold, or stainless steel.


The tubular elements 1 may be manufactured from a hollow tube with an approximately constant thickness corresponding to the desired thickness. The shape of the tubular elements may be formed either by laser cutting followed by electrochemical polishing, or by chemical or electrochemical treatment.


The tubular elements may alternatively be manufactured from a sheet of approximately constant thickness corresponding to the desired thickness of the stent. The geometric configuration of the tubular elements can be obtained either by laser cutting followed by electrochemical polishing, or by chemical or electrochemical treatment. The sheet cut in this way is then rolled up to form a cylinder and welded to give the desired final structure.


After assembly of the tubular elements 1 into a stent of the desired length, the stent can be deployed in a manner known per se. In the case of a stent utilising mechanically forced expansion, the insertion system will preferably comprise a balloon catheter onto which the stent will be crimped 15 in the unexpanded state before being introduced into an insertion tube for guiding it to the site to be treated.


The stent of the invention can be intended for both temporary or permanent placement in the duct or vessel to be treated.

Claims
  • 1. A stent comprising: a tubular body made up of a plurality of separate, radially expandable, tubular elements aligned along a common longitudinal axis, each tubular element being physically unconnected to any other tubular element when the tubular elements are radially expanded,wherein at least some of the tubular elements each comprise a plurality of closed cell elements, each closed cell element joined to a circumferentially-adjacent closed cell element by a circumferentially-extending linking member, each circumferentially-extending linking member being attached to two circumferentially-neighboring closed cell elements at respective spaced apart attachment points,wherein each closed-cell element comprises a pair of side members narrowing inwardly towards a side hinge to form a waist portion,wherein at least some of the closed cell elements comprise an inter-engaging element engageable with a corresponding inter-engaging element on an adjacent tubular element holding the adjacent tubular elements together when engaged, at least in an unexpanded condition of the stent,wherein the inter-engaging element comprises the pair of side members narrowing inwardly towards side hinge forming the waist portion such that two waist portions on circumferentially adjacent closed cell elements act together to retain the corresponding inter-engaging element on the adjacent tubular element;wherein corresponding inter-engaging elements are movable relative to each other along the longitudinal axis when engaged allowing longitudinal movement between adjacent interlocked adjacent tubular elements so as to allow for increased flexibility of the stent in the unexpanded configuration and reduce shortening of the stent during expansion.
  • 2. A stent as claimed in claim 1 wherein the tubular elements are also compressible.
  • 3. A stent as claimed in claim 1 wherein each closed cell element is expandable in the circumferential direction of the tubular element, thus allowing the tubular element to expand and contract.
  • 4. A stent as claimed in claim 3 wherein each closed cell element is positioned symmetrically with respect to the circumferential linking members.
  • 5. A stent as claimed in claim 3 wherein each closed cell element comprises two attachment points, each of which joins to a respective circumferential linking member, and wherein the closed cell element is capable of expanding from a first position in which the attachment points are a first distance apart, to a second position in which the attachment points are a second distance apart, wherein the first distance is less than the second distance.
  • 6. A stent as claimed in claim 5 wherein, between said attachment points, each closed cell element comprises proximal and distal members, spaced apart from each other in the direction of the longitudinal axis, said proximal and distal members being capable of bending to accommodate the expansion from the first position to the second position, wherein the proximal and distal members include the side members in each respective closed cell element.
  • 7. A stent as claimed in claim 6 wherein the plurality of closed cell element comprises circumferentially spaced end hinge members joining the proximal and distal members of each closed cell element, wherein an end of the proximal and distal members of each closed cell element are joined together at a respective end hinge member.
  • 8. A stent as claimed in claim 7 wherein each end hinge member is attached at one end of a respective circumferentially-extending linking member, the other end of the linking member having attached thereto the opposite end hinge member of the next adjacent closed cell element.
  • 9. A stent as claimed in claim 6 wherein each of the proximal and distal members comprises a flexible member joining the attachment points.
  • 10. A stent as claimed in claim 6 wherein each of the proximal and distal members comprises two or more relatively rigid side members joined by the side hinge.
  • 11. A stent as claimed in claim 1 wherein said side members together form the shape of a rhombus.
  • 12. A stent as claimed in claim 1 wherein each of said side members is of rectilinear shape.
  • 13. A stent as claimed in claim 1 wherein all of the closed cell elements making up each tubular element are of the same shape.
  • 14. A stent as claimed in claim 1 wherein some of the closed cell elements making up each tubular element are of a different shape to the remainder.
  • 15. A stent as claimed in claim 1 wherein an exterior surface of the tubular body is equipped with wells which open onto the exterior surface, said wells being suitable to contain one or more therapeutic agents.
  • 16. A stent as claimed in claim 15 in which the wells comprise holes or grooves opening into the exterior surface of the stent.
  • 17. A stent as claimed in claim 16 wherein the holes or grooves are blind, such that the holes or grooves do not pass completely through the material of the stent.
  • 18. A stent as claimed in claim 16 wherein the holes or grooves pass through to an interior of the stent.
  • 19. A stent as claimed in claim 18 in which an inner end of the hole or groove is plugged by a material which prevents or considerably reduces the flow of a therapeutic agent therethrough.
  • 20. A stent as claimed in claim 19 wherein said material contains a therapeutic agent.
  • 21. A stent as claimed in claim 15 wherein the closed cell elements are formed with blocks on each of which are formed one or more of said wells.
  • 22. A stent as claimed in claim 15 wherein at least some of said wells contain multiple therapeutic agents arranged in layers so as to release in sequence.
  • 23. A stent as claim in claim 1, wherein the inter-engaging elements of adjacent tubular elements are configured to engage one another so as to interlock adjacent stents in the unexpanded configuration and are dis-engaged in the expanded configuration so as to inhibit shortening of the stent during expansion.
Priority Claims (2)
Number Date Country Kind
0121980.7 Sep 2001 GB national
02252698 Apr 2002 EP regional
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 10/489,181 filed Mar. 10, 2004, now abandoned, which is a National Stage Entry of PCT Application No. PCT/EP02/09931, filed Sep. 5, 2002, which claims priority to both European Patent Application No. 02252698.2, filed Apr. 16, 2002, and British Patent Application No. 0121980.7, filed Sep. 11, 2001. The entire contents of each of the above patent applications is fully incorporated herein by reference.

US Referenced Citations (455)
Number Name Date Kind
4069825 Akiyama Jan 1978 A
4468224 Enzmann et al. Aug 1984 A
4512338 Balko Apr 1985 A
4564014 Fogarty et al. Jan 1986 A
4580568 Gianturco Apr 1986 A
4681110 Wiktor Jul 1987 A
4690684 McGreevy et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4748982 Horzewski et al. Jun 1988 A
4762129 Bonzel Aug 1988 A
4770176 McGreevy et al. Sep 1988 A
4775337 Van Wagener et al. Oct 1988 A
4776337 Palmaz Oct 1988 A
4886062 Wiktor Dec 1989 A
4891225 Langer et al. Jan 1990 A
4988356 Crittenden et al. Jan 1991 A
4994066 Voss Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
5013318 Spranza, III May 1991 A
5035706 Giantureo et al. Jul 1991 A
5040548 Yock Aug 1991 A
5061273 Yock Oct 1991 A
5064435 Porter Nov 1991 A
5092877 Pinchuk Mar 1992 A
5102417 Palmaz Apr 1992 A
5104404 Wolff Apr 1992 A
5122154 Rhodes Jun 1992 A
5135535 Kramer Aug 1992 A
5192297 Hull Mar 1993 A
5195984 Schatz Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5217495 Kaplan et al. Jun 1993 A
5219355 Parodi et al. Jun 1993 A
5226913 Pinchuk Jul 1993 A
5246421 Saab Sep 1993 A
5273536 Savas Dec 1993 A
5282824 Gianturco Feb 1994 A
5300085 Yock Apr 1994 A
5312415 Palermo May 1994 A
5334187 Fischell et al. Aug 1994 A
5391172 Williams et al. Feb 1995 A
5421955 Lau et al. Jun 1995 A
5445646 Euteneuer et al. Aug 1995 A
5456713 Chuter Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5470315 Adams Nov 1995 A
5478349 Nicholas Dec 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5490837 Blaeser et al. Feb 1996 A
5496346 Horzewski et al. Mar 1996 A
5501227 Yock Mar 1996 A
5507768 Lau et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514093 Ellis et al. May 1996 A
5514154 Lau et al. May 1996 A
5527354 Fontaine et al. Jun 1996 A
5531735 Thompson Jul 1996 A
5534007 St. Germain et al. Jul 1996 A
5549551 Peacock, III et al. Aug 1996 A
5549563 Kronner Aug 1996 A
5549635 Solar Aug 1996 A
5554181 Das Sep 1996 A
5562725 Schmitt et al. Oct 1996 A
5571086 Kaplan et al. Nov 1996 A
5593412 Martinez et al. Jan 1997 A
5607444 Lam Mar 1997 A
5607463 Schwartz et al. Mar 1997 A
5628775 Jackson et al. May 1997 A
5634928 Fischell et al. Jun 1997 A
5639274 Fischell et al. Jun 1997 A
5662675 Polanskyj Stockert et al. Sep 1997 A
5670161 Healy et al. Sep 1997 A
5676654 Ellis et al. Oct 1997 A
5683451 Lenker et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5693085 Buirge et al. Dec 1997 A
5697948 Marin et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5702418 Ravenscroft Dec 1997 A
5709701 Parodi Jan 1998 A
5716393 Lindenberg et al. Feb 1998 A
5722669 Shimizu et al. Mar 1998 A
5723003 Winston et al. Mar 1998 A
5735869 Fernandez-Aceytuno Apr 1998 A
5741323 Pathak et al. Apr 1998 A
5749848 Jang et al. May 1998 A
5749921 Lenker et al. May 1998 A
5755772 Evans et al. May 1998 A
5755776 Al-Saadon May 1998 A
5755781 Jayaraman May 1998 A
5769882 Fogarty et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5776141 Klein et al. Jul 1998 A
5797951 Mueller et al. Aug 1998 A
5800519 Sandock Sep 1998 A
5807398 Shaknovich Sep 1998 A
5824040 Cox et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5833694 Poncet Nov 1998 A
5836964 Richter et al. Nov 1998 A
5843092 Heller et al. Dec 1998 A
5855563 Kaplan et al. Jan 1999 A
5858556 Eckert et al. Jan 1999 A
5870381 Kawasaki et al. Feb 1999 A
5879370 Fischell et al. Mar 1999 A
5891190 Boneau Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5899935 Ding May 1999 A
5902332 Schatz May 1999 A
5919175 Sirhan Jul 1999 A
5921971 Agro et al. Jul 1999 A
5922020 Klein et al. Jul 1999 A
5941869 Patterson et al. Aug 1999 A
5951585 Cathcart et al. Sep 1999 A
5961536 Mickley et al. Oct 1999 A
5968069 Dusbabek et al. Oct 1999 A
5972027 Johnson Oct 1999 A
5976107 Mertens et al. Nov 1999 A
5976155 Foreman et al. Nov 1999 A
5980484 Ressemann et al. Nov 1999 A
5980486 Enger Nov 1999 A
5980514 Kupiecki et al. Nov 1999 A
5980552 Pinchasik et al. Nov 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5997563 Kretzers et al. Dec 1999 A
6004328 Solar Dec 1999 A
6007517 Anderson Dec 1999 A
6022359 Frantzen Feb 2000 A
6022374 Imran Feb 2000 A
6033434 Borghi Mar 2000 A
6036725 Avellanet Mar 2000 A
6039721 Johnson et al. Mar 2000 A
6042589 Marianne Mar 2000 A
6056722 Jayaraman May 2000 A
6063111 Hieshima et al. May 2000 A
6066155 Amann et al. May 2000 A
6068655 Seguin et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6090063 Makower et al. Jul 2000 A
6090136 McDonald et al. Jul 2000 A
6102942 Ahari Aug 2000 A
6106530 Harada Aug 2000 A
RE36857 Euteneuer et al. Sep 2000 E
6120522 Vrba et al. Sep 2000 A
6123712 Di Caprio et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129756 Kugler Oct 2000 A
6132460 Thompson Oct 2000 A
6139572 Campbell et al. Oct 2000 A
6143016 Bleam et al. Nov 2000 A
6165167 Delaloye Dec 2000 A
6165210 Lau et al. Dec 2000 A
6171334 Cox Jan 2001 B1
6179878 Duerig Jan 2001 B1
6183509 Dibie Feb 2001 B1
6187034 Frantzen Feb 2001 B1
6190402 Horton et al. Feb 2001 B1
6196995 Fagan Mar 2001 B1
6200337 Moriuchi et al. Mar 2001 B1
6238991 Suzuki May 2001 B1
6241691 Ferrera et al. Jun 2001 B1
6241758 Cox Jun 2001 B1
6248122 Klumb et al. Jun 2001 B1
6251132 Ravenscroft et al. Jun 2001 B1
6251134 Alt et al. Jun 2001 B1
6254612 Hieshima Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6258117 Camrud et al. Jul 2001 B1
6264688 Herklotz et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270524 Kim Aug 2001 B1
6273895 Pinchuk et al. Aug 2001 B1
6273911 Cox et al. Aug 2001 B1
6273913 Wright et al. Aug 2001 B1
6287291 Bigus et al. Sep 2001 B1
6312458 Golds Nov 2001 B1
6315794 Richter Nov 2001 B1
6319277 Rudnick et al. Nov 2001 B1
6322586 Monroe et al. Nov 2001 B1
6325823 Horzewski et al. Dec 2001 B1
6334871 Dor et al. Jan 2002 B1
6340366 Wijay Jan 2002 B2
6344272 Oldenburg et al. Feb 2002 B1
6348065 Brown et al. Feb 2002 B1
6350277 Kocur Feb 2002 B1
6357104 Myers Mar 2002 B1
6361558 Hieshima et al. Mar 2002 B1
6375676 Cox Apr 2002 B1
6379365 Diaz Apr 2002 B1
6383171 Gifford et al. May 2002 B1
6409753 Brown et al. Jun 2002 B1
6415696 Erickeson et al. Jul 2002 B1
6416543 Hilaire et al. Jul 2002 B1
6419693 Fariabi Jul 2002 B1
6425898 Wilson et al. Jul 2002 B1
6428811 West et al. Aug 2002 B1
6451025 Jervis Sep 2002 B1
6451050 Rudakov et al. Sep 2002 B1
6464720 Boatman et al. Oct 2002 B2
6468298 Pelton Oct 2002 B1
6468299 Stack et al. Oct 2002 B2
6485510 Camrud et al. Nov 2002 B1
6488694 Lau et al. Dec 2002 B1
6488702 Besselink Dec 2002 B1
6511468 Cragg et al. Jan 2003 B1
6520986 Martin et al. Feb 2003 B2
6520987 Plante Feb 2003 B1
6527789 Lau et al. Mar 2003 B1
6527799 Shanley Mar 2003 B2
6530944 West et al. Mar 2003 B2
6540777 Stenzel Apr 2003 B2
6551350 Thornton et al. Apr 2003 B1
6555157 Hossainy Apr 2003 B1
6562067 Mathis May 2003 B2
6569180 Sirhan et al. May 2003 B1
6575993 Yock Jun 2003 B1
6579305 Lashinski Jun 2003 B1
6579309 Loos et al. Jun 2003 B1
6582394 Reiss et al. Jun 2003 B1
6582460 Cryer Jun 2003 B1
6585756 Strecker Jul 2003 B1
6592549 Gerdts et al. Jul 2003 B2
6599296 Gillick et al. Jul 2003 B1
6599314 Mathis Jul 2003 B2
6602226 Smith et al. Aug 2003 B1
6602282 Yan Aug 2003 B1
6605062 Hurley et al. Aug 2003 B1
6605109 Fiedler Aug 2003 B2
6607553 Healy et al. Aug 2003 B1
6629992 Bigus et al. Oct 2003 B2
6645517 West Nov 2003 B2
6645547 Shekalim et al. Nov 2003 B1
6656212 Ravenscroft et al. Dec 2003 B2
6660031 Tran et al. Dec 2003 B2
6660381 Halas et al. Dec 2003 B2
6663660 Dusbabek et al. Dec 2003 B2
6666883 Seguin et al. Dec 2003 B1
6676693 Belding et al. Jan 2004 B1
6676695 Solem Jan 2004 B2
6679909 McIntosh et al. Jan 2004 B2
6685730 West et al. Feb 2004 B2
6692465 Kramer Feb 2004 B2
6699280 Camrud et al. Mar 2004 B2
6699281 Vallana et al. Mar 2004 B2
6699724 West et al. Mar 2004 B1
6702843 Brown Mar 2004 B1
6709379 Brandau et al. Mar 2004 B1
6709440 Callol et al. Mar 2004 B2
6712827 Ellis et al. Mar 2004 B2
6712845 Hossainy Mar 2004 B2
6723071 Gerdts et al. Apr 2004 B2
6736842 Healy et al. May 2004 B2
6743219 Dwyer et al. Jun 2004 B1
6743251 Eder Jun 2004 B1
6761734 Suhr Jul 2004 B2
6778316 Halas et al. Aug 2004 B2
6800065 Duane et al. Oct 2004 B2
6825203 Pasternak et al. Nov 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6849084 Rabkin et al. Feb 2005 B2
6852252 Halas et al. Feb 2005 B2
6855125 Shanley Feb 2005 B2
6858034 Hijlkema et al. Feb 2005 B1
6878161 Lenker Apr 2005 B2
6884257 Cox Apr 2005 B1
6893417 Gribbons et al. May 2005 B2
6896695 Mueller et al. May 2005 B2
6913619 Brown et al. Jul 2005 B2
6918928 Wolinsky et al. Jul 2005 B2
6939376 Shulz et al. Sep 2005 B2
6945989 Betelia et al. Sep 2005 B1
6945995 Nicholas Sep 2005 B2
6951053 Padilla et al. Oct 2005 B2
6962603 Brown et al. Nov 2005 B1
6964676 Gerberding et al. Nov 2005 B1
6991646 Clerc et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
7005454 Brocchini et al. Feb 2006 B2
7022132 Kocur Apr 2006 B2
7037327 Salmon et al. May 2006 B2
7090694 Morris et al. Aug 2006 B1
7101840 Brocchini et al. Sep 2006 B2
7137993 Acosta et al. Nov 2006 B2
7141063 White et al. Nov 2006 B2
7147655 Chermoni Dec 2006 B2
7147656 Andreas et al. Dec 2006 B2
7169172 Levine et al. Jan 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7182779 Acosta et al. Feb 2007 B2
7192440 Andreas et al. Mar 2007 B2
7208001 Coyle et al. Apr 2007 B2
7220755 Betts et al. May 2007 B2
7238197 Sequin et al. Jul 2007 B2
7241308 Andreas et al. Jul 2007 B2
7244336 Fischer et al. Jul 2007 B2
7270668 Andreas et al. Sep 2007 B2
7294146 Chew et al. Nov 2007 B2
7300456 Andreas et al. Nov 2007 B2
7309350 Landreville et al. Dec 2007 B2
7314480 Eidenschink et al. Jan 2008 B2
7320702 Hammersmark et al. Jan 2008 B2
7323006 Andreas et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7351255 Andreas Apr 2008 B2
7534449 Saltzman et al. May 2009 B2
8016870 Chew et al. Sep 2011 B2
20010020154 Bigus et al. Sep 2001 A1
20010020173 Klumb et al. Sep 2001 A1
20010020181 Layne Sep 2001 A1
20010035902 Iddan et al. Nov 2001 A1
20010044595 Reydel et al. Nov 2001 A1
20010044632 Daniel et al. Nov 2001 A1
20010049547 Moore Dec 2001 A1
20020037358 Barry et al. Mar 2002 A1
20020052642 Cox et al. May 2002 A1
20020091439 Baker et al. Jul 2002 A1
20020092536 LaFontaine et al. Jul 2002 A1
20020107560 Richter Aug 2002 A1
20020111671 Stenzel Aug 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20020128706 Osypka Sep 2002 A1
20020138132 Brown Sep 2002 A1
20020151924 Shiber Oct 2002 A1
20020151955 Tran et al. Oct 2002 A1
20020156496 Chermoni Oct 2002 A1
20020168317 Daighighian et al. Nov 2002 A1
20020177890 Lenker Nov 2002 A1
20020183763 Callol et al. Dec 2002 A1
20020188343 Mathis Dec 2002 A1
20020188347 Mathis Dec 2002 A1
20020193873 Brucker et al. Dec 2002 A1
20030045923 Bashiri Mar 2003 A1
20030093143 Zhao et al. May 2003 A1
20030097169 Brucker et al. May 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114919 McQuiston et al. Jun 2003 A1
20030114922 Iwasaka et al. Jun 2003 A1
20030125791 Sequin et al. Jul 2003 A1
20030125800 Shulze et al. Jul 2003 A1
20030125802 Callol et al. Jul 2003 A1
20030135259 Simso Jul 2003 A1
20030135266 Chew et al. Jul 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139797 Johnson et al. Jul 2003 A1
20030139798 Brown et al. Jul 2003 A1
20030163085 Tanner et al. Aug 2003 A1
20030176909 Kusleika Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030195609 Berenstein Oct 2003 A1
20030199821 Gerdts et al. Oct 2003 A1
20030204238 Tedeschi Oct 2003 A1
20030208223 Kleiner Nov 2003 A1
20030212447 Euteneuer Nov 2003 A1
20030225446 Hartley Dec 2003 A1
20040024450 Shulze et al. Feb 2004 A1
20040030380 Shulze et al. Feb 2004 A1
20040044395 Nelson Mar 2004 A1
20040073290 Chouinard Apr 2004 A1
20040093061 Acosta et al. May 2004 A1
20040093067 Israel May 2004 A1
20040106979 Goicoechea Jun 2004 A1
20040111145 Serino et al. Jun 2004 A1
20040117008 Wnendt et al. Jun 2004 A1
20040143322 Litvack et al. Jul 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040181239 Dorn et al. Sep 2004 A1
20040186551 Kao et al. Sep 2004 A1
20040193245 Deem et al. Sep 2004 A1
20040215312 Andreas et al. Oct 2004 A1
20040230285 Gifford, III et al. Nov 2004 A1
20040243217 Andersen et al. Dec 2004 A1
20040249434 Andreas et al. Dec 2004 A1
20050010276 Acosta et al. Jan 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050038505 Shulze et al. Feb 2005 A1
20050049673 Andreas et al. Mar 2005 A1
20050080474 Andreas et al. Apr 2005 A1
20050080475 Andreas et al. Apr 2005 A1
20050085897 Bonsignore Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050125051 Eidenschink et al. Jun 2005 A1
20050131008 Betts et al. Jun 2005 A1
20050143827 Globerman et al. Jun 2005 A1
20050165378 Heinrich et al. Jul 2005 A1
20050209674 Kutscher et al. Sep 2005 A1
20050222671 Schaeffer et al. Oct 2005 A1
20050228477 Grainger et al. Oct 2005 A1
20050245637 Hossainy et al. Nov 2005 A1
20050288764 Snow et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060069424 Acosta et al. Mar 2006 A1
20060173529 Blank Aug 2006 A1
20060200223 Andreas et al. Sep 2006 A1
20060206190 Chermoni Sep 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060229706 Shulze et al. Oct 2006 A1
20060271150 Andreas et al. Nov 2006 A1
20060271151 McGarry et al. Nov 2006 A1
20060282147 Andreas et al. Dec 2006 A1
20060282149 Kao Dec 2006 A1
20060282150 Olson et al. Dec 2006 A1
20060287726 Segal et al. Dec 2006 A1
20070027521 Andreas et al. Feb 2007 A1
20070043419 Nikolchev et al. Feb 2007 A1
20070067012 George et al. Mar 2007 A1
20070088368 Acosta et al. Apr 2007 A1
20070088420 Andreas et al. Apr 2007 A1
20070088422 Chew et al. Apr 2007 A1
20070100423 Acosta et al. May 2007 A1
20070100424 Chew et al. May 2007 A1
20070106365 Andreas et al. May 2007 A1
20070118202 Chermoni May 2007 A1
20070118203 Chermoni May 2007 A1
20070118204 Chermoni May 2007 A1
20070129733 Will et al. Jun 2007 A1
20070135906 Badylak et al. Jun 2007 A1
20070156225 George et al. Jul 2007 A1
20070156226 Chew et al. Jul 2007 A1
20070179587 Acosta et al. Aug 2007 A1
20070219612 Andreas et al. Sep 2007 A1
20070219613 Kao et al. Sep 2007 A1
20070265637 Andreas et al. Nov 2007 A1
20070270936 Andreas et al. Nov 2007 A1
20070276461 Andreas et al. Nov 2007 A1
20070281117 Kaplan et al. Dec 2007 A1
20070292518 Ludwig Dec 2007 A1
20080004690 Robaina Jan 2008 A1
20080046067 Toyokawa Feb 2008 A1
20080071345 Hammersmark et al. Mar 2008 A1
20080077229 Andreas et al. Mar 2008 A1
20080091257 Andreas et al. Apr 2008 A1
20080097299 Andreas et al. Apr 2008 A1
20080097574 Andreas et al. Apr 2008 A1
20080125850 Andreas et al. May 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080147162 Andreas et al. Jun 2008 A1
20080177369 Will et al. Jul 2008 A1
20080199510 Ruane et al. Aug 2008 A1
20080208311 Kao et al. Aug 2008 A1
20080208318 Kao et al. Aug 2008 A1
20080234795 Snow et al. Sep 2008 A1
20080234798 Chew et al. Sep 2008 A1
20080234799 Acosta et al. Sep 2008 A1
20080243225 Satasiya et al. Oct 2008 A1
20080249607 Webster et al. Oct 2008 A1
20080269865 Snow et al. Oct 2008 A1
20090076584 Mao et al. Mar 2009 A1
20090105686 Snow et al. Apr 2009 A1
20090149863 Andreas et al. Jun 2009 A1
20090228088 Lowe Sep 2009 A1
20090234428 Snow et al. Sep 2009 A1
20090264979 Kao et al. Oct 2009 A1
20100004729 Chew et al. Jan 2010 A1
Foreign Referenced Citations (69)
Number Date Country
1 953 1659 Mar 1997 DE
196 30 469 Jan 1998 DE
199 50 756 Aug 2000 DE
101 03 000 Aug 2002 DE
0 203 945 Dec 1986 EP
0 274 129 Jul 1988 EP
0 282 143 Sep 1988 EP
0 505 686 Sep 1992 EP
0 533 960 Mar 1993 EP
0 596 145 May 1994 EP
0 714 640 Jun 1996 EP
0 947 180 Oct 1999 EP
1 258 230 Nov 2002 EP
1 266 638 Dec 2002 EP
1 277 449 Jan 2003 EP
1 290 987 Mar 2003 EP
1 318 765 Jun 2003 EP
1 523 959 Apr 2005 EP
1 523 960 Apr 2005 EP
2277875 Nov 1994 GB
03-133446 Jun 1991 JP
10-503663 Apr 1998 JP
10-295823 Nov 1998 JP
2000-516486 Dec 2000 JP
2001-190687 Jul 2001 JP
2004-121343 Apr 2004 JP
WO 9526695 Oct 1995 WO
WO 9529647 Nov 1995 WO
WO 9626689 Sep 1996 WO
WO 9633677 Oct 1996 WO
WO 9639077 Dec 1996 WO
WO 9746174 Dec 1997 WO
WO 9748351 Dec 1997 WO
WO 9805270 Feb 1998 WO
WO 9820810 May 1998 WO
WO 9837833 Sep 1998 WO
WO 9858600 Dec 1998 WO
WO 9901087 Jan 1999 WO
WO 9965421 Dec 1999 WO
WO 0012832 Mar 2000 WO
WO 0015151 Mar 2000 WO
WO 0025841 May 2000 WO
WO 0032136 Jun 2000 WO
WO 0041649 Jul 2000 WO
WO 0050116 Aug 2000 WO
WO 0056237 Sep 2000 WO
WO 0062708 Oct 2000 WO
WO 0072780 Dec 2000 WO
WO 0170297 Sep 2001 WO
WO 0191918 Dec 2001 WO
WO 02085253 Oct 2002 WO
WO 02098326 Dec 2002 WO
WO 03022178 Mar 2003 WO
WO 03047651 Jun 2003 WO
WO 03051425 Jun 2003 WO
WO 03075797 Sep 2003 WO
WO 2004017865 Mar 2004 WO
WO 2004043299 May 2004 WO
WO 2004043301 May 2004 WO
WO 2004043510 May 2004 WO
WO 2004052237 Jun 2004 WO
WO 2005009295 Feb 2005 WO
WO 2005013853 Feb 2005 WO
WO 2006036939 Apr 2006 WO
WO 2006047520 May 2006 WO
WO 2007035805 Mar 2007 WO
WO 2007053187 May 2007 WO
WO 2007146411 Dec 2007 WO
WO 2008005111 Jan 2008 WO
Related Publications (1)
Number Date Country
20090248137 A1 Oct 2009 US
Continuations (1)
Number Date Country
Parent 10489181 US
Child 12481792 US